Research Matters

Click here to view previous editions of Research Matters and Research News and Updates.




Latest News

Research Newsletter
January 20, 2015  

Skin Diseases Research Center (SDRC)

The Skin Diseases Research Center is funded by a grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases. The goal of the Center is to foster translational and basic research in cutaneous biology and skin diseases. The SDRC sponsors innovative research through its Pilot and Feasibility (P&F) Program and plans to support three new P&F projects for funding for one year with an annual budget of $25,000 (direct costs). Projects are supported with the understanding that the PI will subsequently apply for NIH or equivalent funding using preliminary data acquired during the P&F project period.

Application Deadline: Feb. 27, 2015

For more information visit the CTSC pilot programs webpage.

 
New Facilities and Administrative (F&A) Rate for Use in Proposals

Negotiations with the Department of Health and Human Services (DHHS) regarding the University’s F&A rates have concluded. DHHS has approved a (3) three year F&A rate of 58.5% for CWRU, which is a 1.5 percentage point change from our previous rate of 57%. This rate will be effective through June 2016.

The new F&A rate should be used when preparing proposal budgets for awards with an anticipated start date of July 1, 2013 or after.

Read the full notice of this change at: https://ora.ra.cwru.edu/research/docs/2012.10.08_Facilities_and_Administrative_rate.pdf.

 
amfAR, The Foundation for AIDS Research

amfAR, The Foundation for AIDS Research, has announced the availability of funding to support research relevant to exploring HIV persistence and the potential for HIV eradication. amfAR has established a new funding mechanism known as Impact Grants to support the in-depth development of concepts where preliminary data have indicated genuine promise in curing HIV. Impact Grants are conducted over a four-year funding period with up to $2,000,000 in total funding (including up to 20% indirect costs) and should include basic, animal and clinical (in vivo or ex vivo) research. Impact Grants aim to directly inform clinical efforts to safely eliminate or control latent/persistent HIV reservoirs. Priority will be given to projects with a clear pathway to development of an implementable intervention in humans.

Total Cost Maximum: $2,000,000

Performance Period: 4 years (July 1, 2015 – June 30, 2019)

Portal Request Form Deadline: Friday, February 27, 2015, 3:00 PM ET
Letter of Intent Submission Deadline: Tuesday, March 3, 2015, 3:00 PM ET
Hardcopy of Signed Face Page By Mail: Tuesday, March 24, 2015

For more information and to review the complete RFP visit the amfAR website.

 
NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC)

The NIH Center for Accelerated Innovation at Cleveland Clinic (NCAI-CC) Announces the Request for Applications (RFA) for the third funding cycle.

Funding is available for promising emerging technologies directed towards diagnosis, treatment or management of cardiovascular, pulmonary, blood or sleep-related disorders. NCAI-CC is seeking projects such as therapeutics (e.g. drugs, biologics), preventatives, diagnostics, devices, tools, etc., in order to facilitate their translation to commercialized products that improve patient care and enhance health. The NCAI-CC will provide funding and project assistance to advance the development of high priority early-stage technologies within the mission areas of the NHLBI (cardiovascular, lung, blood and sleep disorders). Expert assistance will be provided in areas required for early technology development, including commercial opportunity assessment, intellectual property, clinical and regulatory, reimbursement, business, legal and project management.

Eligibility: Investigators from the Cleveland Clinic, Case Western Reserve University, The Ohio State University,Cincinnati Children’s Hospital, and University of Cincinnati

Letter of Intent Deadline: February 10, 2015

For more information visit the NCAI-CC website.

 
National Center for Accelerated Innovations (NCAI)

The Office of Translation and Innovation will host an information session on the National Center for Accelerated Innovations (NCAI) program, including details on the current RFA, led by Mark Low, Managing Director for the NCAI-Cleveland Clinic and Mark Chance, Vice Dean for Research in the CWRU School of Medicine.

The information session will be held next Monday, January 26 from 12n - 1pm in BRB 932.

All interested investigators are encouraged to attend. If you are coming from outside the School of Medicine, please stop by the security desk on the ground floor of the Biomedical Research Building and they will give you access to the elevators.

Drs. Low and Chance, among others, will be on hand to help answer any questions you have about this innovations program. The NCAI is currently running it's third funding cycle RFA. This regional funding opportunity is a great chance to move your translational research project to the next level.

Letter of Intent deadline is February 10, 2015

Please RSVP to Anne DeChant or to som-translation-innovation@case.edu

For more information on the RFA visit the NCAI-CC website.

 

If you have news or information that you wish to have included in this update, please send it via e-mail to Tracy Wilson-Holden at tracy.wilson-holden@case.edu no later than 5 pm on the Monday of the week that the update is to be distributed. If you know of individuals who may be interested in receiving this update, please forward this e-mail to them. To subscribe or unsubscribe to Case Research News, email your request to Tora Williams at tora.williams@case.edu.

Please note: At the time of this transmission, all links functioned. However, Case Research News cannot guarantee that the information will not move or be deleted.